]>

Table 5: Ongoing treatment studies evaluating MoAbs in endometrial cancer patients.

Protocol number Disease stage Target therapy Adjuvant treatment Study phase PI NCT01010126 Endometrial cancer Bevacizumab Temsirolimus Phase II Charles Erlichman, MD NCT00977574 Endometrial cancer Bevacizumab Temsirolimus Carboplatin ixabepilone Paclitaxel temsirolimus Phase II Carol Aghajanian, MD NCT01005329 Endometrial cancer Bevacizumab Carboplatin Cisplatin Phase II Akila Viswanathan, MD Paclitaxel radiotherapy NCT01367002 Uterine serous Trastuzumab Carboplatin Paclitaxel Phase II Alessandro D Santin, M.D. NCT01256268 Endometrial Cancer Ridaforolimus Paclitaxel Carboplatin Phase I Robert Wenham, M.D. NCR01244438 Endometrial Cancer with FGFR mutation FP-1039 / Phase II Sarah Thayer NCT01065246 Epithelial Carcinomas Catumaxomab Phase II Jalid Sehouli, MD